MS

Muthukaruppan Srinivasan

Active Director Director DIN 03299981
DIN 03299981 First appointment Jan 2007 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 5 active board seats
Past companies 1 historical roles
Total affiliations 6 Since Jan 2007
Shareholding value •••• Premium profile

About Muthukaruppan Srinivasan

Data last updated:

Muthukaruppan Srinivasan is a Director at Cu-V-Kar Genetic Medicine Private Limited (since 2007), Director at Hfa Formulations Private Limited (since 2019) and Director at Viencee Pharma Science Private Limited (since 2017), and holds 2 more current directorships. The companies operate in Pharma and Paper. The 4 current companies with reported revenue have a combined latest revenue of ₹72.32 Cr; the largest is Cu-V-Kar Genetic Medicine Private Limited at ₹55.11 Cr (FY 2024). Earlier, Muthukaruppan Srinivasan was a Director at Consonance Technology Solutions Private Limited (from 2019).

DIN 03299981
Primary Designation Director
Industry Pharma
First Appointment 04 Jan 2007
Oldest Company Age 19 yrs
Largest company Cu-V-Kar Genetic Medicine Private Limited · ₹55.11 Cr (FY 2024)
Combined revenue ₹72.32 Cr across 4 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director04 Jan 20072007₹55.11 Cr (FY 2024)Active
Hfa Formulations Private Limited U33110TN2015PTC099069
Director14 Jun 20192015₹15.65 Cr (FY 2024)Active
Director11 Jul 20172017₹1.54 Cr (FY 2024)Active
Director05 Jul 20232023₹1.1 Lakh (FY 2025)Active
Mm Pharma Medicines Private Limited U21002TN2023PTC163812
Director20 Sep 20232023Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director14 Jun 20192008Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Board colleagues of Muthukaruppan Srinivasan

Directorship timeline

Open interactive timeline →
Cu-V-Kar Genetic Medicine Private Limited
Hfa Formulations Private Limited
Viencee Pharma Science Private Limited
Consonance Technology Solutions Private Limited
Premium access

Shareholding and investment profile for Muthukaruppan Srinivasan

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Muthukaruppan Srinivasan

Muthukaruppan Srinivasan currently holds 5 directorships: Cu-V-Kar Genetic Medicine Private Limited (Director, since 04 Jan 2007, revenue ₹55.11 Cr (FY 2024)); Hfa Formulations Private Limited (Director, since 14 Jun 2019, revenue ₹15.65 Cr (FY 2024)); Viencee Pharma Science Private Limited (Director, since 11 Jul 2017, revenue ₹1.54 Cr (FY 2024)); Cu-V-Kar Pharmacuticals Private Limited (Director, since 05 Jul 2023, revenue ₹1.1 Lakh (FY 2025)); Mm Pharma Medicines Private Limited (Director, since 20 Sep 2023).

Muthukaruppan Srinivasan was first appointed on 04 Jan 2007 as Director at Cu-V-Kar Genetic Medicine Private Limited. The most recent appointment on record is 20 Sep 2023 at Mm Pharma Medicines Private Limited.

The 4 current companies of Muthukaruppan Srinivasan that report revenue have a combined latest revenue of ₹72.32 Cr: Cu-V-Kar Genetic Medicine Private Limited ₹55.11 Cr (FY 2024); Hfa Formulations Private Limited ₹15.65 Cr (FY 2024); Viencee Pharma Science Private Limited ₹1.54 Cr (FY 2024); Cu-V-Kar Pharmacuticals Private Limited ₹1.1 Lakh (FY 2025).

Muthukaruppan Srinivasan held 1 earlier board appointment: Consonance Technology Solutions Private Limited (Director, from 14 Jun 2019).

The current boards of Muthukaruppan Srinivasan's companies include Ramkumar Srinivasan (Cu-V-Kar Genetic Medicine Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available